Multiple Islet Peptide Administration in Type 1 Diabetes (MultiPepT1De)
Status:
Completed
Trial end date:
2018-04-06
Target enrollment:
Participant gender:
Summary
Type 1 diabetes is an autoimmune disease in which the insulin secreting βcells of the
pancreas are destroyed such that the patient is reliant on injection of insulin to adequately
control blood glucose levels for the remainder of his/her life. The autoimmune process
targets proteins in beta-cells which are termed autoantigens. This is a Phase 1 study using a
novel investigational medicinal product (IMP) known as MultiPepT1De in a study of safety and
tolerability of administration in patients with recent onset Type 1 diabetes. MultiPepT1De is
a mixture of peptides from islet auto antigens. The mixture has been designed to induce or
restore immunological tolerance to the beta-cell and thus control or limit autoimmunity to
protect beta-cells